跳至主要内容
临床试验/NCT03024476
NCT03024476已完成2 期

Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance: Prospective, Randomized, Open, Blinded Outcome Evaluation, and Feasibility Trial

Seoul National University Bundang Hospital3 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2016年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
67
试验地点
3
主要终点
Rate of patients who responded to the calls for breakthrough visit

研究概览

简要总结

BOSS-Trial I is a phase 2 clinical trial with the following objectives;

  1. to prove the feasibility of a Bluetooth-equipped sphygmomanometer system in real-world clinical practice and wireless connection to the main server;
  2. to prove the feasibility of the BP management strategy, including the pre-specified BP range, BP management algorithm, and behavioral; and
  3. to gather information for the phase 3 trial including BP variability indices and their potentials as a treatment guidance.

详细描述

  • Elevated blood pressure is an established risk factor for recurrent stroke and vascular events in ischemic stroke survivors, but

  • Current guideline (JNC VIII) has omitted or only partially covered a number of practical and important issues as follow;

  • When and how we measure blood pressure?

  • Is it justifiable to apply the same blood pressure threshold for office BP and home BP?

  • Should stroke survivors be treated by the same BP goal for non-stroke subjects?

  • Is it justifiable to apply the universal BP threshold for different mechanisms of ischemic stroke?

  • Is it really about only blood pressure or might it really be "beyond blood pressure?"

  • Lifestyle modification should accompany all the pharmacological intervention but is usually in adequate to initiate behavioral changes.

  • Frequent BP measurement at home will provide more detailed and reliable information than occasional office BP's.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ischemic stroke survivors within 7 days after onset
  • ≥19 year-old male or female
  • Medically and neurologically stabilized enough to take BP-lowering medication
  • Mean systolic blood pressure ≥135 mm Hg during two days between at least 24 hours after onset and randomization (whether BP-lowering medication was prescribed or not)
  • Capable of taking oral medication
  • Capable of operating a wireless Bluetooth-equipped sphygmomanometer system and being expected to follow required procedures of the clinical trial
  • Patients who provided written informed consent

排除标准

  • Pregnant, puerperium ≤30 days or on breastfeeding
  • enrolled in other interventional clinical trial
  • Being transferred to rehabilitation center or institutionalized
  • Being expected to have cerebral artery interventions within 3 months after randomization
  • Known allergic reactions to olmesartan, amlodipine or hydrochlorothiazide
  • Known severe hepatic disease
  • Advanced kidney dysfunction requiring dialysis
  • Being unlikely, in the opinion of the investigator, to comply with the clinical trial protocol or being unsuitable for any other reason.

研究组 & 干预措施

Intensive management arm

Experimental

Description:

  • Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan
  • Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).
  • Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.
  • Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.

干预措施: Behavioral intensification (Behavioral)

Intensive management arm

Experimental

Description:

  • Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan
  • Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).
  • Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.
  • Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.

干预措施: Pharmacological intensification based on olmesartan (Drug)

Intensive management arm

Experimental

Description:

  • Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan
  • Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).
  • Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.
  • Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.

干预措施: Bluetooth-equipped sphygmomanometer (Device)

Control arm

Active Comparator

Description:

  • Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.
  • Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).

干预措施: Bluetooth-equipped sphygmomanometer (Device)

结局指标

主要结局

Rate of patients who responded to the calls for breakthrough visit

时间窗: At 3 months after randomization

ratio of subjects response over the breakthrough visit calls

Retention of included participants

时间窗: At 3 months after randomization

Ratio of completed subject over randomized subjects in each group

Control of blood pressure

时间窗: At 3 months after randomization

ratio of subjects with well-controlled BP in each group

Recruitment time to prespecified number of subjects

时间窗: At 3 months after randomization

Difference in days between recruitment of the first subject and last subject

Frequencies of calls for breakthrough visit

时间窗: At 3 months after randomization

Mean and standard deviation of breakthrough visits per each patient in the intensive management group

次要结局

  • Weighted hit score of BP(At 3 months after randomization)
  • Hypotensive events(Until 3 months after randomization)
  • Vascular events(At 3 months after randomization)
  • Frequency of out-of-range measurement(At 3 months after randomization)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hee-Joon Bae

Professor

Seoul National University Bundang Hospital

研究点 (3)

Loading locations...

相似试验